Introduction
============

Esophagus cancer is a common malignant tumor in the digestive tract, with incidence rate ranking fourth among all tumors ([@b1-ol-0-0-9511]). Although the incidence rate of Barrett\'s adenocarcinoma has increased rapidly in western countries, esophageal squamous cell carcinoma (ESCC) still holds a dominant position in East Asia and China ([@b2-ol-0-0-9511]). Currently there are many treatment methods, such as operation, chemotherapy and radiotherapy, but the 5-year survival rate of patients with esophagus cancer is still lower than 40%, so new diagnosis and treatment methods still need to be further studied and explored ([@b3-ol-0-0-9511]).

B-cell lymphoma 2 (Bcl-2) associated X protein (Bax) is an important pro-apoptosis protein in Bcl-2 family, which has three structural domains: BH1, BH2 and BH3 ([@b4-ol-0-0-9511]). Under normal conditions, Bax proteins mainly exist in the cytoplasm. When cells receive various apoptosis signals, Bax proteins will transfer from the cytoplasm onto the mitochondrial membrane, and recognize Bcl-2 proteins on the membrane through BH3 structural domain, binding to Bcl-2 to form the Bax-Bcl-2 heterodimer, thereby inhibiting the anti-apoptosis effect of Bcl-2 proteins ([@b5-ol-0-0-9511]). At the same time, Bax proteins can also form the Bax-Bax homodimer on the mitochondrial membrane, thus increasing the permeability of mitochondrial membrane and releasing cytochrome C into the cytoplasm to activate the cascade apoptosis response. Therefore, Bax is an important regulator of the mitochondrial apoptosis signaling pathway ([@b6-ol-0-0-9511],[@b7-ol-0-0-9511]).

Currently, there are few reports on the correlation between Bax gene polymorphism and tumors, but the G(−248)A site of Bax gene promoter has been studied ([@b8-ol-0-0-9511]). Studies have found that the polymorphism of G(−248)A site can down-regulate the activity of Bax promoter, and affect the Bax gene transcription and protein expression, ultimately increasing the Bcl-2/Bax ratio, and inhibiting the apoptosis process of tumor cells ([@b9-ol-0-0-9511]--[@b11-ol-0-0-9511]).

In order to investigate the correlation between Bax gene polymorphism, clinicopathological features and survival prognoses of ESCC patients, this study utilized polymerase chain reaction-restricted fragment length polymorphism (PCR-RFLP) to detect the Bax gene polymorphism of genomic DNA in peripheral blood in ESCC patients, and adopted immunohistochemistry to detect the Bax expression in ESCC tissues, and analysed the correlation between Bax gene polymorphism and Bax protein expression, and then clinicopathological parameters and survival prognosis of ESCC patients were studied.

Patients and methods
====================

### Materials

The paraffin-embedded specimens of tumor tissues of 75 ESCC patients were collected. A total of 37 males and 38 females aged 24--78 years were included in this study, with a median age of 52 years. All the patients received operation in the Affiliated Jinling Hospital of Nanjing Medical University (Nanjing, China) from June 2009 to March 2012. The patients were pathologically diagnosed with ESCC and underwent operative treatment for the first time without receiving chemotherapy, radiotherapy and other treatments. This study was reviewed and approved by the Ethics Committee of the Affiliated Jinling Hospital of Nanjing Medical University, and all patients or their families signed the informed consent.

Tools included in this study: DNA extraction kits and reverse transcription-polymerase chain reaction (RT-PCR) kits (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA); restriction endonuclease Aci I (New England Biolabs, Wilbury WayHitchin, Herts, UK); rabbit monoclonal Bax antibody (1:100; cat. no. ab32503, Abcam; Cambridge, MA, USA); immunohistochemical staining kits SP-9001 (Zhongshan Goldenbridge Biotechnology, Beijing, China); primer synthesis (Takara, Dalian, China).

### Detection of Bax genotypes of ESCC patients via PCR-RFLP

At admission, 5 ml fasting venous blood was collected from all patients and stored in a refrigerator at 4°C after heparin anticoagulation. Then the chromosomal DNA in peripheral blood karyocytes was extracted according to the instructions of DNA extraction kit, followed by PCR amplification reaction. The forward and reverse primers of enzyme digestion PCR: 5′-CGGGGTTATCTCTTGGGC-3′ and 5′-GTGAGAGCCCCGCTGAAC-3′. The specific reaction conditions are as follows: 95°C for 5 min, 95°C for 30 sec, 55°C for 30 sec, 72°C for 1 min, in total 40 cycles; extension at 72°C for 5 min. Finally, the enzyme digestion of PCR products was performed via the restriction endonuclease Aci I.

### Detection of Bax protein expression in tissues of ESCC patients via immunohistochemistry

The Bax protein expression in tissues of ESCC patients was detected via streptomycin avidin-peroxidase (SP) method. The tissue section was dewaxed routinely by xylene and hydrated by gradient ethanol; then 3% H~2~O~2~ solution was used to eliminate the activity of endogenous peroxidase, followed by high pressure boiling and antigen retrieval. The primary rabbit monoclonal Bax antibody was added dropwise and the mixture was placed in the refrigerator at 4°C overnight. Then, the mixture was washed with phosphate buffered saline (PBS) (0.01 M) and added with secondary goat anti-rabbit (HRP) IgG antibody (1:2,000; cat. no. ab6721; Abcam) for incubation at 37°C for 1 h, followed by another wash with PBS, color development via diaminobenzidine (DAB), re-staining via hematoxylin, and photographing under the TE2000-U microscope (Nikon, Tokyo, Japan).

The staining results were evaluated by the two-level scoring method. First, based on the staining intensity: No color, 0 point; pale yellow, 1 point; brown yellow, 2 points; dark brown, 3 points. Then, based on the percentage of positive cells: Percentage of positive cells \<5%, 0 point; 5--25%, 1 point; 26--50%, 2 points; \>50%, 3 points. The two scores were added up: \>3 points, positive expression; ≤2 points, negative expression. Finally, the results were statistically analyzed.

### Correlation of Bax genotypes with pathological parameters of ESCC tissues

In this study, the number of cases with AA genotype was small, so AG and AA genotypes were combined into AG+AA group. A total of 75 ESCC patients were divided into GG group and AG+AA group. According to clinical data of patients, the correlation between Bax genotypes and pathological parameters of patients was analyzed via χ^2^ test.

### Correlation of Bax genotypes with survival prognosis of ESCC patients

All of 75 patients were followed up after operation for 5 years and the follow-up rate was 100%. The survival time was from the 1st day after operation to the death of patients or the last date of follow-up; the statistical analyses were performed each month.

### Statistics processing

SPSS software (version 17.0, SPPSS Inc., Chicago, IL, USA) was used for the data processing in this study. Data were presented as mean ± SD. χ^2^ test was used for the intergroup comparison of enumeration data; Spearman\'s test was used for the correlation analysis; Kaplan-Meier method was used for the univariate survival analysis and Log-rank method was used to detect the differences of survival curve. P≤0.05 was considered to indicate a statistically significant difference.

Results
=======

### Detection of Bax gene polymorphism in ESCC patients via PCR-RFLP

PCR-RFLP results showed that the GG genotype appeared in 256 and 96 bp fragments, AG genotype appeared in 352 and 256 bp fragments, and AA genotype appeared in 352 bp fragment. According to the data statistics of all patients, the number of cases and distribution frequencies of GG, AG and AA genotypes were 50 (66.67%), 16 (21.33%) and 9 (12%), respectively ([Fig. 1](#f1-ol-0-0-9511){ref-type="fig"}).

### Detection of Bax protein expression in pathological tissues via immunohistochemistry

The immunohistochemical detection results revealed that the positive immunohistochemical staining of Bax showed brown yellow or dark brown, and Bax proteins mainly existed in the cytoplasm. According to the statistical results of staining scores, the positive expression rate of Bax in ESCC tissues was 42.67% (32/75) ([Fig. 2](#f2-ol-0-0-9511){ref-type="fig"}).

### Relationship between Bax gene polymorphism and Bax protein expression

Among 75 ESCC patients, there were 4 cases with positive Bax and AG/AA genotypes, 28 cases with positive Bax and GG genotype, 21 cases with negative Bax and AG/AA genotypes and 22 cases with negative Bax and GG genotype. Spearman\'s analysis was used to analyze the relationship between Bax gene polymorphism and Bax protein expression, and the results showed that the Bax gene polymorphism was positively correlated with the Bax protein expression (r=0.793; P\<0.01; [Table I](#tI-ol-0-0-9511){ref-type="table"}).

### Correlation of Bax gene polymorphism with clinicopathological indexes of ESSC

The analysis results of the correlations between Bax gene polymorphism and clinicopathological indexes of ESSC are shown in [Table II](#tII-ol-0-0-9511){ref-type="table"}. χ^2^ test revealed that the Bax gene polymorphism was associated with the outer membrane infiltration, differentiation degree, lymphatic metastasis and clinical staging of patients (P\<0.01), but not related to the sex and age (P\>0.05).

### Relationship between Bax gene polymorphism and survival prognosis of patients

A total of 75 ESCC patients were followed up; there were 29 survivors and 46 deaths during 5 years. Kaplan-Meier survival curve of 75 patients with Bax gene polymorphism was analyzed, and the results showed that the prognosis of patients with AG+AA genotypes was favorable, while that of patients with GG genotype was poor ([Fig. 3](#f3-ol-0-0-9511){ref-type="fig"}). The differences in total survival curve were analyzed via Log-rank test, and the effect of Bax gene polymorphism on the overall survival rate of ESCC patients was statistically significant (P\<0.01).

Discussion
==========

Esophagus cancer is a malignant tumor with a high incidence rate, and its incidence and death rate tops the list in malignant tumors ([@b1-ol-0-0-9511]). The incidence rate of esophagus cancer in developing countries is higher than that in developed countries, and the new-onset patients in developing countries every year account for \~80% of the total in the world ([@b12-ol-0-0-9511]). In China, esophagus cancer has a relatively high incidence rate, ranking fifth in malignant tumors, and its death rate ranks fourth in malignant tumors. In some high-risk areas, esophagus cancer even becomes the most common malignant tumor, seriously affecting people\'s life and health ([@b13-ol-0-0-9511]). Pathogenesis and mechanisms of occurrence and development of esophagus cancer are very complicated; currently, studies have shown that the causes of esophagus cancer mainly include environmental factors, dietary habit, smoking, drinking and genetic factors ([@b14-ol-0-0-9511],[@b15-ol-0-0-9511]).

Studies have found that the Bax expression in esophagus cancer tissues is significantly lower than that in normal esophageal epithelial tissues and the Bax expression is negatively correlated with the tumor differentiation degree of patients ([@b16-ol-0-0-9511]). It was found in the study on colon cancer that the Bax protein is a key indicator of prognosis of benign colorectal cancer ([@b17-ol-0-0-9511],[@b18-ol-0-0-9511]). Recent study has shown that L3, a novel target gene, is closely related to the proliferation of tumor cells and has an important correlation with the ratio of bcl-2/bax in colon cancer tissues ([@b19-ol-0-0-9511]). Katkoori *et al* found that the tumor staging and metastasis of patients with positive Bax expression are superior to those of patients with negative Bax expression; besides, the survival analyses showed that the Bax protein is an influencing factor of survival of patients ([@b20-ol-0-0-9511]).

Single nucleotide polymorphism (SNP) is one of the important factors of differences in hereditary characters of different individuals, which is the most basic molecular foundation of genetic polymorphism, leading to differences in the susceptibilities of individuals to diseases and drugs ([@b21-ol-0-0-9511]). At present, there are many studies on Bax G(−248)A polymorphism in leukemia. Previous evidence showed that AG/AA genotypes reduce chemotherapy resistance and prolong the survival time of patients with chronic lymphocytic leukemia ([@b22-ol-0-0-9511]). Many studies have shown that the Bax protein is lowly expressed in tissues of patients with AG/AA genotypes, mainly because the A allele can inhibit the Bax protein expression ([@b23-ol-0-0-9511],[@b24-ol-0-0-9511]). In the study on breast cancer, it was found that the Bax protein expression is negatively correlated with the differentiation degree, lymphatic metastasis and distal metastasis of breast cancer, and the clinicopathological indexes of patients with negative Bax expression are poorer than those of patients with positive Bax expression ([@b25-ol-0-0-9511]).

To further investigate the effect of Bax gene polymorphism on Bax protein expression in tumor tissues of ESCC patients, as well as its effects on pathological parameters and survival prognoses of ESCC patients, this study detected three genotypes (AA, AG and GG) of Bax G(−248)A SNP in 75 ESCC patients via PCR-RFLP, and found that the number of cases and distribution frequencies of GG, AG and AA genotypes of Bax polymorphism in ESCC patients were 50 (66.67%), 16 (21.33%) and 9 (12%), respectively. The immunohistochemical results revealed that the positive expression rate of Bax in ESSC tissues was 42.67%. Moreover, χ^2^ test revealed that the Bax protein expression was associated with the Bax gene polymorphism. Furthermore, combined with clinicopathological parameters of patients, it was found that the Bax gene polymorphism was related to the outer membrane infiltration, differentiation degree, lymphatic metastasis and clinical staging of patients. The overall 5-year survival rate of patients was 38.6% (29/75). Univariate Kaplan-Meier survival analyses were performed to analyze effects of Bax gene polymorphism on overall survival curve of patients; the results showed that the prognosis of patients with AG+AA genotypes was favorable, while that of patients with GG genotype was poor.

In conclusion, Bax gene polymorphism is related to the Bax gene expression, tumor staging and lymphatic metastasis of ESCC patients, which is an influencing factor of overall survival rate of ESCC patients, and can be used as a reference index for prognosis evaluation of ESCC patients.
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###### 

Correlation between Bax gene polymorphisms and protein expression in esophageal squamous cell carcinoma tissues.

             Bax G(−248)A single nucleotide polymorphism                
  ---------- --------------------------------------------- ---- ------- --------
  Positive   4                                             28   0.793   \<0.01
  Negative   21                                            22           

Bax, B-cell lymphoma-2 associated X protein.

###### 

Correlation between Bax gene polymorphism and clinicopathological indexes of ESSC (n, %).

  Pathological parameter        Case   AG/AA genotype (%)   GG genotype (%)   χ^2^    P-value
  ----------------------------- ------ -------------------- ----------------- ------- ---------
  Sex                                                                         0.11    \>0.05
    Male                        37     13 (35.14)           24 (64.86)                
    Female                      38     12 (31.58)           26 (68.42)                
  Age (years)                                                                 0.43    \>0.05
    ≥50                         41     15 (36.59)           26 (63.41)                
    \<50                        34     10 (29.41)           24 (70.59)                
  Outer membrane infiltration                                                 17.03   \<0.01
    Yes                         43     6 (13.95)            37 (86.05)                
    No                          32     19 (59.38)           13 (40.63)                
  Differentiation degree                                                      19.47   \<0.01
    High                        39     4 (10.26)            35 (89.74)                
    Low                         36     21 (58.33)           15 (41.67)                
  Lymphatic metastasis                                                        7.74    \<0.01
    Yes                         35     6 (17.14)            29 (82.86)                
    No                          40     19 (47.50)           21 (52.50)                
  Clinical staging                                                            8.24    \<0.01
    I--II                       28     15 (53.57)           13 (46.43)                
    III--IV                     47     10 (21.28)           37 (78.72)                

Bax, B-cell lymphoma-2 associated X protein.
